Status:
COMPLETED
Observational Study to Monitor Long-term Immunogenicity and Efficacy of UB 311 Vaccine in Subjects With Alzheimer's Disease
Lead Sponsor:
United Biomedical
Collaborating Sponsors:
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50-80 years
Brief Summary
The purpose of this observational study is to determine whether the vaccine (UB 311), targeting the N-terminal amino acids (1-14) of the amyloid beta peptide, has long-term immunogenicity and efficacy...
Eligibility Criteria
Inclusion
- Individuals with mild to moderate Alzheimer's disease who received three (3) injections of UB 311 in the initial Phase I V118-AD trial
Exclusion
- Individuals with Alzheimer's disease who are currently on prohibited medications, have severe or uncontrolled systemic disease, or are unable or unwilling to comply with study protocol requirements.
Key Trial Info
Start Date :
April 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT01189084
Start Date
April 1 2010
End Date
July 1 2011
Last Update
July 13 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital (NTUH)
Taipei, Taiwan, 10002
2
Taipei Veterans General Hospital
Taipei, Taiwan, 11217